Abstract: This disclosure describes systems, methods, and devices related to adaptation of secure sounding signal. A device may determine a negotiated bandwidth to be used when communicating with a first station device. The device may determine a first bit stream used to generate a cyclic shift diversity (CSD) value based on the negotiated bandwidth, wherein a first number of bits is used for the first bit stream when a first negotiated bandwidth is used, and wherein a second number of bits is used for the first bit stream when a second negotiated bandwidth is used. The device may determine a second bit stream used to generate a random phase. The device may determine a secure a long training field (LTF) based on a combination of the first bit stream and the second bit stream. The device may cause to send a frame to the first station device, wherein the frame comprises the secure LTF.

Abstract: As described herein, photosensitive composition comprises RSnL3, where R is a hydrocarbyl ligand with 1-20 carbon atoms and one or more silicon and/or germanium heteroatoms and L is an acetylide ligand (—C?CA, where A is a silyl group with 0 to 6 carbon atoms or an organo group with 1 to 10 carbon atoms). Methods are described wherein photosensitive compositions are synthesized by reacting RX, where X is a halide, and MSnL3, where M is an alkali metal, alkali earth metal or a pseudo-alkali earth metal, L is an acetylide or a dialkylamide. The radiation sensitive compositions are effective for radiation based patterning, such as with EUV light.

Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Abstract: A multilayer dissolvable solid article and method of making the same is described. The article has two or more flexible, dissolvable, porous sheets. Each of such two or more sheets has a Percent Open Cell Content of from about 80% to 100% and an Overall Average Pore Size of from about 100 ?m to about 2000 ?m. At least two adjacent sheets in such dissolvable solid article have an Adhesion Score (AdS) of no less than 1, while the contacting surfaces of said at least two adjacent sheets are essentially free of adhesives. Preferably, the multilayer dissolvable solid article is essentially free of adhesives.

Abstract: This invention provides a multilayer dissolvable solid article, which comprises two or more flexible, dissolvable, porous sheets. Each of such two or more sheets is characterized by a Percent Open Cell Content of from about 80% to 100% and an Overall Average Pore Size of from about 100 ?m to about 2000 ?m and comprises a water-soluble polymer. At least two adjacent sheets in such dissolvable solid article are characterized by an Adhesion Score (AdS) of no less than 1, while the contacting surfaces of said at least two adjacent sheets are essentially free of adhesives. Preferably, the multilayer dissolvable solid article is essentially free of adhesives.

Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A glass cartridge comprises a cylindrical body portion comprising an outer diameter Dc and an average sidewall thickness Tc, the cylindrical body portion having a first end and a second end opposite the first end; an opening at the first end of the cylindrical body portion; a shoulder extending radially inward from the second end of the cylindrical body portion; and a neck extending from the shoulder and comprising an outer neck diameter NOD that is less than the outer diameter Dc of the cylindrical body portion. The average wall thickness Tc is less than or equal to 0.85*s1, wherein s1 is a wall thickness of a standard glass cartridge defined by ISO 13926-1:2004 having an outer diameter d1 that is closer to the outer diameter Dc than the outer diameter d1 of any other standard glass cartridge defined by ISO 13926-1:2004.

Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.

Abstract: This disclosure describes systems, methods, and devices related to secure sounding signal. A device may generate two or more sounding signals to be sent using two or more antennas to a receiving device across a plurality of symbol intervals. The device may apply a first masking signal to a first sounding signal of the two or more sounding signals over a first symbol interval of the plurality of the symbol intervals. The device may apply a second masking signal to a second sounding signal over a second symbol interval of the plurality of the symbol intervals. The device may cause to send the two or more sounding signals to receiving device using the two or more antennas.

Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.